Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Physical Activity and Cardiovascular Risk among Kidney Transplant Patients.

Kang AW, Garber CE, Eaton CB, Risica PM, Bostom AG.

Med Sci Sports Exerc. 2019 Jan 8. doi: 10.1249/MSS.0000000000001886. [Epub ahead of print]

PMID:
30629045
2.

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG.

Am J Kidney Dis. 2019 Jan;73(1):51-61. doi: 10.1053/j.ajkd.2018.05.015. Epub 2018 Jul 20.

PMID:
30037726
3.

Hypothesis: Potential Utility of Serum and Urine Uromodulin Measurement in Kidney Transplant Recipients?

Bostom AG, Steubl D, Friedman AN.

Transplant Direct. 2017 Oct 6;3(11):e219. doi: 10.1097/TXD.0000000000000737. eCollection 2017 Nov. Review.

4.

Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.

Kalil RS, Carpenter MA, Ivanova A, Gravens-Mueller L, John AA, Weir MR, Pesavento T, Bostom AG, Pfeffer MA, Hunsicker LG.

Am J Kidney Dis. 2017 Dec;70(6):762-769. doi: 10.1053/j.ajkd.2017.06.013. Epub 2017 Aug 9.

PMID:
28801121
5.

Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS.

Am J Transplant. 2017 Sep;17(9):2390-2399. doi: 10.1111/ajt.14258. Epub 2017 Mar 30.

6.

More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients.

Bostom AG, Merhi B, Walker J, Robinson-Bostom L.

World J Transplant. 2016 Dec 24;6(4):658-664. doi: 10.5500/wjt.v6.i4.658. Review.

7.

B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients.

Jarolim P, Claggett BL, Conrad MJ, Carpenter MA, Ivanova A, Bostom AG, Kusek JW, Hunsicker LG, Jacques PF, Gravens-Mueller L, Finn P, Solomon SD, Weiner DE, Levey AS, Pfeffer MA.

Transplantation. 2017 Jan;101(1):182-190. doi: 10.1097/TP.0000000000001080.

8.

Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial.

Weir MR, Gravens-Muller L, Costa N, Ivanova A, Manitpisitkul W, Bostom AG, Diamantidis CJ; FAVORIT Study Investigators.

Transplantation. 2015 May;99(5):1003-8. doi: 10.1097/TP.0000000000000454.

9.

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.

Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW.

Clin Transplant. 2012 Jul-Aug;26(4):E438-46. doi: 10.1111/j.1399-0012.2012.01676.x. Epub 2012 Jul 9.

10.

Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Weiner DE, Carpenter MA, Levey AS, Ivanova A, Cole EH, Hunsicker L, Kasiske BL, Kim SJ, Kusek JW, Bostom AG.

Am J Transplant. 2012 Sep;12(9):2437-45. doi: 10.1111/j.1600-6143.2012.04101.x. Epub 2012 May 17.

11.

Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.

Bostom AG, Maclean AA, Maccubbin D, Tipping D, Giezek H, Hanlon WA.

J Clin Lipidol. 2011 Jul-Aug;5(4):281-7. doi: 10.1016/j.jacl.2011.03.455. Epub 2011 May 13.

PMID:
21784373
12.

Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

Ix JH, Ganjoo P, Tipping D, Tershakovec AM, Bostom AG.

Am J Kidney Dis. 2011 Jun;57(6):963-5. doi: 10.1053/j.ajkd.2011.03.010. Epub 2011 Apr 15. No abstract available. Erratum in: Am J Kidney Dis. 2011 Oct;58(4):688. Dosage error in article text.

PMID:
21496982
13.

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M.

Circulation. 2011 Apr 26;123(16):1763-70. doi: 10.1161/CIRCULATIONAHA.110.000588. Epub 2011 Apr 11.

14.

Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia.

Hu S, Shearer GC, Steffes MW, Harris WS, Bostom AG.

Am J Kidney Dis. 2011 Jan;57(1):181-2. doi: 10.1053/j.ajkd.2010.06.029. Epub 2010 Oct 8. No abstract available.

PMID:
20888102
15.

New evidence for the phosphorus-lowering effects of niacin.

Bostom AG.

Am J Kidney Dis. 2010 Jul;56(1):185. doi: 10.1053/j.ajkd.2010.03.032. No abstract available.

PMID:
20620683
16.

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG.

Clin J Am Soc Nephrol. 2010 Apr;5(4):582-9. doi: 10.2215/CJN.07341009. Epub 2010 Mar 18.

17.

Binder blinders-niacin of omission?

Bostom AG.

Am J Kidney Dis. 2010 Apr;55(4):628-30. doi: 10.1053/j.ajkd.2009.12.015. Epub 2010 Jan 15. No abstract available.

PMID:
20079958
18.

Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J; FAVORIT Study Investigators.

Am J Kidney Dis. 2009 Jan;53(1):121-8. doi: 10.1053/j.ajkd.2008.08.010. Epub 2008 Nov 20.

19.

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.

Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J; FAVORIT Investigators.

Am Heart J. 2006 Sep;152(3):448.e1-7.

PMID:
16923411
20.

Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.

Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group.

J Am Soc Nephrol. 2005 Nov;16(11):3397-402. Epub 2005 Sep 14.

Supplemental Content

Loading ...
Support Center